Daxor Announces Agreement With NYU Medical Center for a Frozen Autologous Blood Program

NEW YORK, NY -- (MARKET WIRE) -- May 17, 2007 -- Daxor Corporation (AMEX: DXR), a medical instrumentation and biotechnology company, today announced the receipt of an agreement from NYU Medical Center.

Idant Laboratories, a subsidiary of the Daxor Corporation, has received an agreement from NYU Medical Center for acceptance of its frozen autologous blood program. Idant Laboratories, utilizing FDA approved technology, is able to store an individual's red blood cells in a frozen state for a period of up to 10 years. The Company has developed a Blood Optimization Program (BOP) for which it has filed a methods patent. The BOP incorporates the use of blood volume measurement and storage of one's own blood in a frozen state prior to elective surgery. Most self-storage blood programs involve the donation of blood one to four weeks prior to surgery, which frequently results in anemia at the time of surgery. This program enables individuals to store blood well in advance of any planned surgery so they are not anemic at the time of surgery.

The utilization of the blood volume analyzer enables precise measurement of an individual's blood volume prior to donation, so individuals who have unrecognized anemia will receive treatment and will not donate blood while still anemic. NYU Medical Center's Nuclear Medicine Department has purchased a Daxor BVA-100 Blood Volume Analyzer and will be able to perform blood volume measurements on candidates for the program.

Utilizing one's own blood is preferable to using donor blood because, despite improved screening methods, donor blood poses a number of risks. These include risks of infectious disease transmission and of immunosuppression, a response to imperfectly matched blood in which the immune system becomes less effective. The safest blood is one's own.

Dr. Timothy Hilbert, Medical Director of the NYU Medical Center's Blood Bank, said that, "NYU Medical Center's Blood Bank is happy to facilitate this program which may provide one of the most advanced forms of transfusion therapy available for patients undergoing elective surgery."

Contact Information: Contact Information: Stephen Feldschuh Chief Operating Officer 212-330-8515 Email Contact or Diane Meegan Investor Relations 212-330-8512 Email Contact